Now showing items 1-1 of 1

    • A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. 

      Bendell, JC; Blobe, GC; Cushman, SM; Dellinger, Andrew; Gockerman, J; Hurwitz, HI; Li, H; ... (13 authors) (Cancer Med, 2013-06)
      Targeting multiple regulators of tumor angiogenesis have the potential to improve treatment efficacy. Bevacizumab is a monoclonal antibody directed against vascular endothelial growth factor and ABT-510 is a synthetic analog ...